These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1034 related items for PubMed ID: 19451443

  • 1. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M.
    J Clin Oncol; 2009 Jul 10; 27(20):3303-11. PubMed ID: 19451443
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
    Guo H, Zhu H, Xi Y, Zhang B, Li L, Huang Y, Zhang J, Fu Z, Yang G, Yuan S, Yu J.
    J Nucl Med; 2007 Aug 10; 48(8):1251-8. PubMed ID: 17631554
    [Abstract] [Full Text] [Related]

  • 4. Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer.
    Saad A, Kanate A, Sehbai A, Marano G, Hobbs G, Abraham J.
    Clin Breast Cancer; 2008 Aug 10; 8(4):357-61. PubMed ID: 18757264
    [Abstract] [Full Text] [Related]

  • 5. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
    Liu FY, Yen TC, Chen MY, Lai CH, Chang TC, Chou HH, Hong JH, Chen YR, Ng KK.
    Cancer; 2009 Dec 01; 115(23):5470-80. PubMed ID: 19739235
    [Abstract] [Full Text] [Related]

  • 6. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM.
    J Nucl Med; 2009 May 01; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M.
    Cancer; 2008 Nov 01; 113(9):2422-30. PubMed ID: 18785255
    [Abstract] [Full Text] [Related]

  • 9. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH.
    J Nucl Med; 2008 Dec 01; 49(12):1912-21. PubMed ID: 18997056
    [Abstract] [Full Text] [Related]

  • 10. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ, Zhang YX, Wei H, Jia Q.
    Zhonghua Yi Xue Za Zhi; 2007 Aug 28; 87(32):2253-6. PubMed ID: 18001544
    [Abstract] [Full Text] [Related]

  • 11. FDG PET-CT in the management of primary breast lymphoma.
    Santra A, Kumar R, Reddy R, Halanaik D, Kumar R, Bal CS, Malhotra A.
    Clin Nucl Med; 2009 Dec 28; 34(12):848-53. PubMed ID: 20139815
    [Abstract] [Full Text] [Related]

  • 12. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N, Fujita K, Fujisawa T, Takahashi H, Yoneda M, Abe Y, Inamori M, Kirikoshi H, Kubota K, Saito S, Nakajima A.
    Gan To Kagaku Ryoho; 2008 Jan 28; 35(1):65-70. PubMed ID: 18195530
    [Abstract] [Full Text] [Related]

  • 13. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ.
    J Clin Oncol; 2008 Jul 01; 26(19):3213-21. PubMed ID: 18591556
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
    Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW.
    J Clin Oncol; 2005 Mar 01; 23(7):1420-30. PubMed ID: 15735118
    [Abstract] [Full Text] [Related]

  • 16. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
    Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 1):4218-24. PubMed ID: 16857794
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, Schnyder P, Luthi F, von Schulthess GK, Leyvraz S.
    Eur J Nucl Med Mol Imaging; 2005 Feb 15; 32(2):153-62. PubMed ID: 15690223
    [Abstract] [Full Text] [Related]

  • 19. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
    Karam M, Ata A, Irish K, Feustel PJ, Mottaghy FM, Stroobants SG, Verhoef GE, Chundru S, Douglas-Nikitin V, Oliver Wong CY, Brepoels LM.
    Nucl Med Commun; 2009 Oct 15; 30(10):770-8. PubMed ID: 19657307
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.